Melanoma
MEL · Oncology · 4 drugs · 5 indications
Skin cancer arising from melanocytes. Includes BRAF-mutated and wild-type.
Competitive Landscape (4 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| V940 | MRK | mRNA neoantigen vaccine | mRNA | IM | PHASE3 |
| Fianlimab | REGN | LAG-3 inhibitor (monoclonal antibody) | Monoclonal antibody | IV | PHASE3 |
| Tafinlar + Mekinist | NVS | BRAF + MEK inhibitor combination | Small molecule | Oral | APPROVED |
| Keytruda | MRK | PD-1 inhibitor | Antibody | IV | APPROVED |
Indications (5)
Adjuvant melanoma (resected Stage II-IV)
Unresectable/metastatic melanoma, 1L
Upcoming Catalysts
Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)CLINICAL
MRK2026
Fianlimab - Metastatic Melanoma 1L - Ph3 Topline (RELATIVITY-104)CLINICAL
REGN2026
Fianlimab - Adjuvant Melanoma - Ph3 Topline (RELATIVITY-106)CLINICAL
REGNH2 2026
V940 - Melanoma - Ph3 - Interim (INTerpath-001)CLINICAL
MRKH2 2026
Keytruda - LOE PreparationCOMPETITIVE
MRKOngoing
Data from Supabase · Updated 2026-03-24